- Connecticut AG William Tong announced enforcement actions against companies that allegedly advertised, distributed, or sold so-called “research grade” versions of GLP-1 weight loss drugs in violation of state consumer protection laws.
- The AG sued Triggered Brand for allegedly marketing and selling “research grade” versions of GLP-1 drugs that do not have FDA approval for human use, and issued a Civil Investigative Demand to Made in China, a Chinese international trade platform, over its alleged marketing and sale of “research grade” versions of GLP-1 drugs and the factories that manufacture them.
- The AG also sent letters to weight loss clinics, med spas, and medical practices warning that the FDA has health and safety concerns associated with compounded versions of GLP-1 drugs and that continued marketing and sale may violate state consumer protection laws.
- Other efforts to protect consumers from non-FDA approved versions of GLP-1 drugs include a letter sent by the National Association of Attorneys General requesting that the FDA take action to protect consumers from counterfeit forms of GLP-1 drugs.